Reverse cholesterol transport: High-density lipoprotein's magnificent mile

被引：54
作者：
Peter P. Toth
机构：
[1] Sterling Rock Falls Clinic, Sterling, IL 61081
来源：
Current Atherosclerosis Reports | 2003年 / 5卷 / 5期
关键词：
Cholesteryl Ester; Cholesteryl Ester Transfer Protein; Cholesterol Efflux; Arterioscler Thromb Vasc Biol; Reverse Cholesterol Transport;
D O I：
10.1007/s11883-003-0010-5
中图分类号：
学科分类号：
摘要：
High-density lipoproteins (HDLs) are among the most structurally complex and functionally versatile forms of circulating serum lipoproteins. HDLs undergo extensive enzymatic remodeling during their maturation in serum, interact with highly specific receptors in peripheral tissues and the liver, and are able to exert a variety of antiatherogenic effects (eg, inhibit inflammation, oxidation, and apoptosis). Considerable epidemiologic, clinical, and basic scientific investigation supports the conclusion that HDLs as a molecular class are atheroprotective. One of the most important antiatherogenic functions of HDL is its capacity to drive reverse cholesterol transport, the process by which excess cholesterol in peripheral tissues is extracted and delivered to the liver for disposal. Despite the rapid expansion in our understanding of how HDL antagonizes many of mechanisms etiologic for atherosclerosis and the observation that a low serum level of HDL is the most frequent lipid abnormality in patients with premature coronary artery disease, many physicians still focus inadequate attention on recognizing and treating hypoalphalipoproteinemia. Our current understanding of reverse cholesterol transport reinforces the clinical importance of including HDL screening when evaluating any given patient's risk for cardiovascular disease. Copyright © 2003 by Current Science Inc.
引用
收藏
页码：386 / 393
页数：7
相关论文
共 61 条
[11]  
Li D., Weng S., Yang B., Et al., Inhibition of arterial thrombus formation by apoA-I Milano, Arterioscler. Thromb. Vasc. Biol., 19, pp. 378-383, (1999)
[12]  
Maxfield F.R., Wustner D., Intracellular cholesterol transport, J. Clin. Invest., 110, pp. 891-898, (2002)
[13]  
Tabas I., Consequences of cellular cholesterol accumulation: Basic concepts and physiological implications, J. Clin. Invest., 110, pp. 905-911, (2002)
[14]  
Brooks-Wilson A., Marcil M., Clee S.M., Et al., Mutations in ABCA1 in Tangier disease and familial high-density lipoprotein deficiency, Nat. Genet., 22, pp. 336-345, (1999)
[15]  
Venkateswaran A., Laffitte B.A., Joseph S.B., Et al., Control of cellular cholesterol efflux by the nuclear receptor LXRα, Proc. Natl. Acad. Sci., 97, pp. 12097-12102, (2000)
[16]  
Attie A.D., Kastelein J.P., Hayden M.R., Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis, J. Lipid Res., 42, pp. 1717-1726, (2001)
[17]  
Zha X., Gauthier A., Genest J., Et al., Secretory vesicular transport from the Golgi is altered during ATP-binding cassette protein A1 (ABCA1) mediated cholesterol efflux, J. Biol. Chem., (2003)
[18]  
Oram J.F., ATP-binding cassette transporter A1 and cholesterol trafficking, Curr. Opin. Lipidol., 13, pp. 373-381, (2002)
[19]  
Chroni A., Liu T., Gorshkova I., Et al., The central helices of ApoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux, J. Biol. Chem., 278, pp. 6719-6730, (2003)
[20]  
Vaisman B.L., Lambert G., Amar M., Et al., ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice, J. Clin. Invest., 108, pp. 303-309, (2001)
1234567